Abstract：Hepatitis B virus (HBV) is a non-cytopathic virus, and the liver damage caused by its continuous infection gradually causes liver inflammation, which leads to liver fibrosis, cirrhosis, and eventually causes 80% of Hepatocellular Carcinoma (HCC). Liver is an important organ of metabolism in the body. The abnormal activation of oncogenes and the inactivation of tumor suppressor genes will cause changes in the level and mode of cell metabolism, which is called metabolism reprogramming. Metabolic reprogramming is a key step in the transformation from liver inflammation to cancer. In this study, the expression of key genes of lipid metabolism in HBV-positive cells (or tissues) and control cells (or tissues) was detected by reverse transcription-polymerase chain reaction (RT-PCR), Enzyme-linked Immunosorbent Assay (ELISA) and multiple fluorescence immuno histochemistry, and on this basis, the relationship between their functions and lipid metabolism was analyzed. The results showed that in HepG2.2.15 cells with stable HBV expression and Hep3B cells with stable HBsAg expression, the mRNA expressions of lipid metabolism-related genes HMGCR, SREBP-2 and PSCK9 were significantly up-regulated, and the corresponding protein expression levels were also increased synchronously in the clinicopathological results of hepatocellular carcinoma patients. It is suggested that HBV infection leads to the high expression of corresponding metabolic genes, and HBsAg is the key protein regulating the disorder of lipid metabolism enzyme genes. By analyzing the pathological data of 365 large samples of liver cancer patients, it was found that the high expression of lipid metabolism-related genes in liver cancer tissues has a trend of poor prognosis, suggesting that the disorder of lipid metabolism may be a risk factor affecting the overall survival of liver cancer patients.
Wang Y, Wu T, Hu D, et al. Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein[J]. J Lipid Res. 2018, 59(1): 58-68.
[2]
Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism[J]. Cancer Res. 2009, 69(6): 2163-2166.
[3]
Mullen P J, Yu R, Longo J, et al. The interplay between cell signalling and the mevalonate pathway in cancer[J]. Nat Rev Cancer. 2016, 16(11): 718-731.
[4]
Parsons D W, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme[J]. Science. 2008, 321(5897): 1807-1812.
[5]
Mardis E R, Ding L, Dooling D J, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome[J]. N Engl J Med. 2009, 361(11): 1058-1066.
[6]
Mollinedo F, Gajate C. Lipid rafts as major platforms for signaling regulation in cancer[J]. Adv Biol Regul. 2015, 57: 130-146.
[7]
Clendening J W, Penn L Z. Targeting tumor cell metabolism with statins[J]. Oncogene. 2012, 31(48): 4967-4978.
[8]
Clendening J W, Pandyra A, Boutros P C, et al. Dysregulation of the mevalonate pathway promotes transformation[J]. Proc Natl Acad Sci U S A. 2010, 107(34): 15051-15056.
[9]
Amemiya-Kudo M, Shimano H, Hasty A H, et al. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes[J]. J Lipid Res. 2002, 43(8): 1220-1235.
[10]
Clendening J W, Pandyra A, Li Z, et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma[J]. Blood. 2010, 115(23): 4787-4797.
[11]
Duncan R E, El-Sohemy A, Archer M C. Mevalonate promotes the growth of tumors derived from human cancer cells in vivo and stimulates proliferation in vitro with enhanced cyclin-dependent kinase-2 activity[J]. J Biol Chem. 2004, 279(32): 33079-33084.
[12]
Go G W, Mani A. Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J]. Yale J Biol Med. 2012, 85(1): 19-28.
[13]
Krysa J A, Ooi T C, Proctor S D, et al. Nutritional and Lipid Modulation of PCSK9: Effects on Cardiometabolic Risk Factors[J]. J Nutr. 2017, 147(4): 473-481.
[14]
Nomura M, Liu J, Rovira I I, et al. Fatty acid oxidation in macrophage polarization[J]. Nat Immunol. 2016, 17(3): 216-217.
[15]
Seo Y K, Jeon T I, Chong H K, et al. Genome-wide localization of SREBP-2 in hepatic chromatin predicts a role in autophagy[J]. Cell Metab. 2011, 13(4): 367-375.
[16]
Medina M W, Gao F, Ruan W, et al. Alternative splicing of 3-hydroxy-3-methylglutaryl coenzyme A reductase is associated with plasma low-density lipoprotein cholesterol response to simvastatin[J]. Circulation. 2008, 118(4): 355-362.
[17]
Engelking L J, Mcfarlane M R, Li C K, et al. Blockade of cholesterol absorption by ezetimibe reveals a complex homeostatic network in enterocytes[J]. J Lipid Res. 2012, 53(7): 1359-1368.
